132 related articles for article (PubMed ID: 38510242)
1. Upregulation of Receptor Tyrosine Kinase Activity and Stemness as Resistance Mechanisms to Akt Inhibitors in Breast Cancer.
Tsang T; He Q; Cohen EB; Stottrup C; Lien EC; Zhang H; Lau CG; Chin YR
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291790
[TBL] [Abstract][Full Text] [Related]
2. Modeling Melanoma Heterogeneity In Vitro: Redox, Resistance and Pigmentation Profiles.
Carvalho LADC; Noma IHY; Uehara AH; Siena ÁDD; Osaki LH; Mori MP; Pinto NCS; Freitas VM; Junior WAS; Smalley KSM; Maria-Engler SS
Antioxidants (Basel); 2024 Apr; 13(5):. PubMed ID: 38790661
[TBL] [Abstract][Full Text] [Related]
3. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.
Tian Y; Guo W
Med Sci Monit; 2020 Apr; 26():e920957. PubMed ID: 32273491
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
5. Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.
Muraro E; Montico B; Lum B; Colizzi F; Giurato G; Salvati A; Guerrieri R; Rizzo A; Comaro E; Canzonieri V; Anichini A; Del Vecchio M; Mortarini R; Milione M; Weisz A; Pizzichetta MA; Simpson F; Dolcetti R; Fratta E; Sigalotti L
Front Immunol; 2024; 15():1336566. PubMed ID: 38510242
[TBL] [Abstract][Full Text] [Related]
6. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas.
Wang J; Huang SK; Marzese DM; Hsu SC; Kawas NP; Chong KK; Long GV; Menzies AM; Scolyer RA; Izraely S; Sagi-Assif O; Witz IP; Hoon DSB
J Invest Dermatol; 2015 Feb; 135(2):532-541. PubMed ID: 25243790
[TBL] [Abstract][Full Text] [Related]
8. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
Dugo M; Nicolini G; Tragni G; Bersani I; Tomassetti A; Colonna V; Del Vecchio M; De Braud F; Canevari S; Anichini A; Sensi M
Oncotarget; 2015 Mar; 6(7):5118-33. PubMed ID: 25742786
[TBL] [Abstract][Full Text] [Related]
9. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
Herr R; Halbach S; Heizmann M; Busch H; Boerries M; Brummer T
Oncogene; 2018 Mar; 37(12):1576-1593. PubMed ID: 29326440
[TBL] [Abstract][Full Text] [Related]
10. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor is a determinant of melanoma targeted drug resistance.
Samarkina A; Youssef MK; Ostano P; Ghosh S; Ma M; Tassone B; Proust T; Chiorino G; Levesque MP; Goruppi S; Dotto GP
Nat Commun; 2023 Oct; 14(1):6498. PubMed ID: 37838724
[TBL] [Abstract][Full Text] [Related]
12. Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches.
Hasan N; Nadaf A; Imran M; Jiba U; Sheikh A; Almalki WH; Almujri SS; Mohammed YH; Kesharwani P; Ahmad FJ
Mol Cancer; 2023 Oct; 22(1):168. PubMed ID: 37803407
[TBL] [Abstract][Full Text] [Related]
13. Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy.
Redondo-Muñoz M; Rodriguez-Baena FJ; Aldaz P; Caballé-Mestres A; Moncho-Amor V; Otaegi-Ugartemendia M; Carrasco-Garcia E; Olias-Arjona A; Lasheras-Otero I; Santamaria E; Bocanegra A; Chocarro L; Grier A; Dzieciatkowska M M; Bigas C; Martin J; Urdiroz-Urricelqui U; Marzo F; Santamaria E; Kochan G; Escors D; Larrayoz IM; Heyn H; D'Alessandro A; Attolini CS; Matheu A; Wellbrock C; Benitah SA; Sanchez-Laorden B; Arozarena I
Nat Metab; 2023 Sep; 5(9):1544-1562. PubMed ID: 37563469
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series.
Chang M; Samlowski W; Meoz R
Oncotarget; 2023 Jul; 14():709-718. PubMed ID: 37417890
[TBL] [Abstract][Full Text] [Related]
15. Cellular Uptake of Silica Particles Influences EGFR Signaling Pathway and is Affected in Response to EGF.
Sousa de Almeida M; Roshanfekr A; Balog S; Petri-Fink A; Rothen-Rutishauser B
Int J Nanomedicine; 2023; 18():1047-1061. PubMed ID: 36874146
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
